Want to see NUVB full AI Analyst Report?
NUVB Stock Chart & Stats
$5.08
-$0.19(-5.85%)
At close: 4:00 PM EST
$5.08
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$1.81 - $9.75
Previous CloseN/A
Volume977.37K
Average Volume (3M)4.41M
Market Cap
$1.99B
Enterprise Value$1.74B
Total Cash (Recent Filing)$533.73M
Total Debt (Recent Filing)$9.83M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding348,201,970
10 Day Avg. Volume4,941,951
30 Day Avg. Volume4,414,404
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue12.13
Enterprise Value/Gross Profit13.24
Enterprise Value/Ebitda-13.37
Forecast
1Y Price Target
$14.40Price Target Upside183.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$201.20M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue With Strong Gross MarginsRapid top‑line growth combined with very high gross margins indicates attractive unit economics and meaningful commercial traction for lead products. Durable margin profile supports reinvestment in R&D and commercialization and improves scalability as volumes rise, underpinning medium‑term profitability potential.
Robust Cash Reserves And Funding FlexibilityA large cash balance plus available credit provides runway to fund launches, late‑stage trials, and regulatory work without immediate capital raises. This reduces near‑term refinancing risk, allows strategic optionality, and gives management time to convert clinical momentum into sustainable revenue growth over the next several quarters.
Clinical Differentiation And Guideline RecognitionRobust CNS efficacy, prolonged DOR/PFS, and NCCN guideline inclusion create a durable competitive advantage in ROS1 NSCLC. These clinical outcomes support physician preference, longer on‑therapy durations, and improved lifetime patient value, aiding first‑line adoption and sustainable market share gains.
Bears Say
Persistent Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow indicate the business still consumes material cash to support commercialization and clinical programs. Over 2–6 months this burn necessitates reliance on cash reserves or financings, constraining flexibility and raising the risk of dilution or program slowdowns if revenue growth stalls.
Convertible Notes Introduce Future Dilution RiskReplacing secured debt with long‑dated convertibles reduces near‑term secured leverage but creates contingent equity issuance. If shares trade below conversion economics, conversion or settlement choices can dilute existing holders and complicate capital structure, impacting long‑term shareholder value and future M&A or financing flexibility.
Plateaued New Patient Starts And Diagnostic GapsA steady absolute run‑rate of new starts and low community molecular testing limit addressable market capture. Structural dependence on improved diagnostic uptake means growth requires sustained investment in testing adoption or market development, otherwise revenue expansion may be constrained despite clinical differentiation.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio Inc’s price range in the past 12 months?
Nuvation Bio Inc lowest stock price was $1.81 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio Inc’s market cap?
Nuvation Bio Inc’s market cap is $1.99B.
When is Nuvation Bio Inc’s upcoming earnings report date?
Nuvation Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 31 days.
How were Nuvation Bio Inc’s earnings last quarter?
Nuvation Bio Inc released its earnings results on May 04, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.038.
Is Nuvation Bio Inc overvalued?
According to Wall Street analysts Nuvation Bio Inc’s price is currently Undervalued.
Does Nuvation Bio Inc pay dividends?
Nuvation Bio Inc does not currently pay dividends.
What is Nuvation Bio Inc’s EPS estimate?
Nuvation Bio Inc’s EPS estimate is -0.15.
How many shares outstanding does Nuvation Bio Inc have?
Nuvation Bio Inc has 348,201,970 shares outstanding.
What happened to Nuvation Bio Inc’s price movement after its last earnings report?
Nuvation Bio Inc reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Nuvation Bio Inc?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.40 (183.46% Upside)
$14.40 (183.46% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $118.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
178.04%
12-Months-Change
Fundamentals
Return on Equity
-44.10%
Trailing 12-Months
Asset Growth
23.91%
Trailing 12-Months
Company Description
Nuvation Bio Inc
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
NUVB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum for Iptrozy: robust physician awareness (97%), growing first‑line mix (>50% of new starts), meaningful sequential product revenue growth (18% QoQ to $18.5M), and differentiated durability and CNS efficacy (50‑month PFS/DOR in TKI‑naive; 66% intracranial RR). Financially, the quarter was bolstered by a near‑term collaboration upfront (~$60M) and a healthy cash position ($533.7M) with $50M credit available. Key challenges include a steady absolute level of new patient starts (~200/quarter), testing shortfalls in the community (<50% in some centers) that limit incidence capture, upward pressure on gross‑to‑net (targeting stabilization in the high‑20s to ~30%), and sizeable operating expenses ($73.5M). Overall, positive clinical differentiation, market access progress, partnerships, and balance sheet strength outweigh the operational and market access headwinds.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$14.40
▲(183.46% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
24.84% Insiders
15.76% Mutual Funds
20.37% Other Institutional Investors
28.26% Public Companies and Individual Investors